Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Menaquinone-7,Ankascin 568-R
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : SunWay Biotech
Deal Size : Undisclosed
Deal Type : Partnership
SunWay Biotech and Gnosis Launch MenaQ7® Metabolic Featuring ANKASCIN® 568-R Ingredient
Details : The partnership aims to launch SunWay's inaugural product, MenaQ7® Metabolic, featuring two key active ingredients, MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R.
Brand Name : MenaQ7
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 14, 2024
Lead Product(s) : Menaquinone-7,Ankascin 568-R
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : SunWay Biotech
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Vitamin K2
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Recipient : NattoPharma
Deal Size : Undisclosed
Deal Type : Acquisition
Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma
Details : This acquisition brings together globally recognized vitamin K2 brands vitaMK7® and MenaQ7® and allows Gnosis by Lesaffre to offer to the market the most complete portfolio of solutions, adapted to each market need and able to satisfy all customers.
Brand Name : MenaQ7
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 25, 2021
Lead Product(s) : Vitamin K2
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Recipient : NattoPharma
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?